在44届摩根大通医疗健康会议（JPM）上，武田制药CEO Christophe Weber携公司最新业务布局与研发管线亮相。作为总部位于东京、业务遍及全球80个国家和地区的生物制药巨头，武田制药2024财年（2024/4/1-2025/3/31）实现营收4.6万亿日元（约合306亿美元），其中美国市场贡献52%营收，欧洲及加拿大市场占比23%，中国市场占4%。研发层面，武田研发聚焦胃肠道与炎症、...
Source Link在44届摩根大通医疗健康会议（JPM）上，武田制药CEO Christophe Weber携公司最新业务布局与研发管线亮相。作为总部位于东京、业务遍及全球80个国家和地区的生物制药巨头，武田制药2024财年（2024/4/1-2025/3/31）实现营收4.6万亿日元（约合306亿美元），其中美国市场贡献52%营收，欧洲及加拿大市场占比23%，中国市场占4%。研发层面，武田研发聚焦胃肠道与炎症、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.